Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib versus placebo in severe indolent or smouldering systemic mastocytosis
2016-001447-39Phase 3Active
- Sponsor
- AB Science
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic mastocytosis (SM) and indolent systemic mastocytosis (ISM) comparing Masitinib with Placebo (2 arms). Primary endpoint: Cumulative response on 3 severe symptoms from week 8 to week 24. Started Mar 2017; status: active.
02
Drugs
masitinib
03
Conditions
systemic mastocytosis (SM)indolent systemic mastocytosis (ISM)
Beyond the preview
Go deeper on 2016-001447-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001447-39.